Organon & Co
$ 7.29
0.83%
27 Feb - close price
- Market Cap 1,897,701,000 USD
- Current Price $ 7.29
- High / Low $ 7.34 / 7.08
- Stock P/E 10.12
- Book Value 2.89
- EPS 0.72
- Next Earning Report 2026-04-30
- Dividend Per Share $0.34
- Dividend Yield 4.7 %
- Next Dividend Date 2026-03-12
- ROA 0.06 %
- ROE 0.31 %
- 52 Week High 15.93
- 52 Week Low 6.15
About
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
Analyst Target Price
$9.29
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-30 | 2025-08-05 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-06 | 2024-05-03 | 2024-02-15 | 2023-11-02 | 2023-08-08 | 2023-05-04 |
| Reported EPS | 0.63 | 1.01 | 1 | 1.02 | 0.9 | 0.87 | 1.12 | 1.22 | 0.88 | 0.87 | 1.31 | 1.08 |
| Estimated EPS | 0.76 | 0.93 | 0.94 | 0.89 | 0.87 | 0.9 | 1.08 | 0.97 | 0.83 | 1.06 | 1.01 | 1.16 |
| Surprise | -0.13 | 0.08 | 0.06 | 0.13 | 0.03 | -0.03 | 0.04 | 0.25 | 0.05 | -0.19 | 0.3 | -0.08 |
| Surprise Percentage | -17.1053% | 8.6022% | 6.383% | 14.6067% | 3.4483% | -3.3333% | 3.7037% | 25.7732% | 6.0241% | -17.9245% | 29.703% | -6.8966% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.8476 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-12 | 2025-12-11 | 2025-09-11 | 2025-06-12 | 2025-03-13 | 2024-12-12 | 2024-09-12 | 2024-06-13 | 2024-03-14 | 2023-12-14 |
| Amount | $0.02 | $0.02 | $0.02 | $0.02 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 |
Next Dividend Records
| Dividend per share (year): | $0.34 |
| Dividend Yield | 4.7% |
| Next Dividend Date | 2026-03-12 |
| Ex-Dividend Date | 2026-02-23 |
Recent News: OGN
2026-02-27 12:52:30
Vanguard Group Inc. increased its stake in Organon & Co. (NYSE:OGN) by 11.3% in Q3, now owning 35,928,403 shares valued at approximately $383.72 million. Despite this significant institutional holding, analysts maintain a "Reduce" consensus rating with an average target price of $8.50, following recent downgrades and missed earnings expectations. Organon also announced a small quarterly dividend of $0.02, representing a 1.1% yield.
2026-02-27 02:51:23
This report provides a comprehensive stock analysis of Organon (NYSE:OGN), a pharmaceutical company focusing on women's health. It covers the company's market capitalization, current share price, valuation, future growth prospects, past performance, financial health, dividends, management, and ownership. The analysis highlights key takeaways from different analyst perspectives, including potential for growth through new products and market expansion, as well as risks such as global pricing pressures and debt obligations.
2026-02-25 03:52:56
Bronstein, Gewirtz & Grossman, LLC is urging Organon & Co. (NYSE: OGN) stockholders who purchased securities before November 3, 2022, and still hold them, to engage in a securities investigation. The firm is investigating potential corporate wrongdoing by Organon and its officers/directors. Investors can assist the investigation at bgandg.com/OGN, and the firm operates on a contingency fee basis.
2026-02-24 01:51:56
Organon has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD) contraceptive. This strategic move strengthens Organon's commitment to women's health with the first hormone-free copper IUD approved in the U.S. in 40 years. The deal involves an initial payment of $27.5 million, with potential sales-based milestone payments up to $505 million and tiered double-digit royalties.
2026-02-23 21:53:26
Organon & Co. (OGN) reported its full-year 2025 financial results, with total revenue of $6.2 billion and adjusted diluted EPS of $3.66, alongside an adjusted EBITDA margin of 30.7%. The company projects 2026 revenue and adjusted EBITDA to be consistent with 2025 figures. Additionally, Organon finalized the sale of its JADA System to Laborie Medical Technologies Corp.
2026-02-23 21:46:15
Organon & Co. (OGN) reported full-year 2025 financial results, with total revenue of $6.2 billion, a 3% decline, and non-GAAP adjusted diluted EPS of $3.66. The company achieved an adjusted EBITDA of $1.91 billion, resulting in a 30.7% adjusted EBITDA margin, and anticipates similar financial performance in 2026. Organon also finalized the sale of its JADA System, a device for postpartum uterine bleeding, to Laborie Medical Technologies Corp.
